Prime Medicine: Soon In The Clinic

Prime Medicine stock analysis: a $548M valuation vs. a best-in-class gene-editing pipeline, key catalysts, M&A upside, and dilution risks. Click to read more.

Summarised by Agaah from Seeking Alpha. Agaah aggregates 36 sources and removes duplicate coverage — all news, one place.